Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities.
MIS-C
SARS-CoV-2
cardiac manifestation
chemokines
cytokines
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 Oct 2023
27 Oct 2023
Historique:
received:
10
08
2023
revised:
12
09
2023
accepted:
27
09
2023
medline:
27
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Multisystem inflammatory syndrome in children (MIS-C), a sequela of severe acute respiratory syndrome coronavirus-2 infection (SARS-CoV2), has been progressively reported worldwide, with cardiac involvement being a frequent presentation. Although the clinical and immunological characteristics of MIS-C with and without cardiac involvement have been described, the immunological differences between cardiac and non-cardiac MIS-C are not well understood. The levels of type 1, type 2, type 17, other proinflammatory cytokines and CC chemokines and CXC chemokines were measured using the Magpix multiplex cytokine assay system in MIS-C children with MIS-C cardiac (MIS-C (C) ( MIS-C children with cardiac manifestations presented with significantly increased levels of cytokines such as IFN-γ, IL-2, TNFα, IL-5, IL-1α, IL-1β, IL-6, IL-10 and IL-12p70 and chemokines such as CCL2, CCL3, CCL11 and CXCL10 in comparison to MIS-C children without cardiac manifestations. Clustering analysis revealed that cytokines and chemokines could clearly distinguish MIS-C children with and without cardiac manifestations. In addition, these responses significantly diminished and normalized 9 months after treatment. This is one of the first studies characterizing and differentiating systemic inflammation in MIS-C with and without cardiac involvement from a low- and middle-income country (LMIC). Our study contributes to the existing body of evidence and advances our knowledge of the immunopathogenesis of MIS-C in children.
Sections du résumé
BACKGROUND
BACKGROUND
Multisystem inflammatory syndrome in children (MIS-C), a sequela of severe acute respiratory syndrome coronavirus-2 infection (SARS-CoV2), has been progressively reported worldwide, with cardiac involvement being a frequent presentation. Although the clinical and immunological characteristics of MIS-C with and without cardiac involvement have been described, the immunological differences between cardiac and non-cardiac MIS-C are not well understood.
METHODS
METHODS
The levels of type 1, type 2, type 17, other proinflammatory cytokines and CC chemokines and CXC chemokines were measured using the Magpix multiplex cytokine assay system in MIS-C children with MIS-C cardiac (MIS-C (C) (
RESULTS
RESULTS
MIS-C children with cardiac manifestations presented with significantly increased levels of cytokines such as IFN-γ, IL-2, TNFα, IL-5, IL-1α, IL-1β, IL-6, IL-10 and IL-12p70 and chemokines such as CCL2, CCL3, CCL11 and CXCL10 in comparison to MIS-C children without cardiac manifestations. Clustering analysis revealed that cytokines and chemokines could clearly distinguish MIS-C children with and without cardiac manifestations. In addition, these responses significantly diminished and normalized 9 months after treatment.
CONCLUSIONS
CONCLUSIONS
This is one of the first studies characterizing and differentiating systemic inflammation in MIS-C with and without cardiac involvement from a low- and middle-income country (LMIC). Our study contributes to the existing body of evidence and advances our knowledge of the immunopathogenesis of MIS-C in children.
Identifiants
pubmed: 38005840
pii: v15112162
doi: 10.3390/v15112162
pmc: PMC10674423
pii:
doi:
Substances chimiques
RNA, Viral
0
Cytokines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID)
Références
Circulation. 2021 Jan 5;143(1):21-32
pubmed: 33166189
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Indian Pediatr. 2023 May 15;60(5):389-390
pubmed: 36896751
World J Pediatr. 2021 Aug;17(4):335-340
pubmed: 34013488
Indian Pediatr. 2020 Nov 15;57(11):1010-1014
pubmed: 32769230
Open Forum Infect Dis. 2021 Jul 06;8(7):ofab279
pubmed: 34322566
Indian J Pediatr. 2022 Oct;89(10):1040-1044
pubmed: 36028606
Pediatrics. 2020 Dec;146(6):
pubmed: 33184170
Lancet Child Adolesc Health. 2021 Jul;5(7):473-482
pubmed: 34043958
Circulation. 2020 Aug 4;142(5):429-436
pubmed: 32418446
Bol Med Hosp Infant Mex. 2021;78(6):642-646
pubmed: 34934208
Children (Basel). 2020 Jul 01;7(7):
pubmed: 32630212
JAMA. 2020 Jul 21;324(3):259-269
pubmed: 32511692
N Engl J Med. 2020 Jul 23;383(4):334-346
pubmed: 32598831
Front Pediatr. 2020 Dec 16;8:626182
pubmed: 33425823
Biomedicines. 2023 Apr 23;11(5):
pubmed: 37238922
Radiology. 2020 Dec;297(3):E283-E288
pubmed: 32515676
Rheumatol Int. 2021 Jan;41(1):19-32
pubmed: 33219837
BMJ. 2020 Jun 3;369:m2094
pubmed: 32493739
Indian J Pediatr. 2023 Jul;90(7):654-659
pubmed: 35511400
J Am Heart Assoc. 2020 Jun 16;9(12):e017224
pubmed: 32441586
SN Compr Clin Med. 2021;3(1):48-59
pubmed: 33437929
Front Med (Lausanne). 2022 Dec 05;9:1050804
pubmed: 36544496
Cell. 2020 Nov 12;183(4):968-981.e7
pubmed: 32966765
N Engl J Med. 2020 Jul 23;383(4):393-395
pubmed: 32598829
Circulation. 2017 Apr 25;135(17):e927-e999
pubmed: 28356445
HSR Proc Intensive Care Cardiovasc Anesth. 2010;2(3):161-75
pubmed: 23441054
Circulation. 2021 Jan 5;143(1):78-88
pubmed: 33166178
J Infect Dis. 2022 Sep 28;226(7):1215-1223
pubmed: 35932220
EBioMedicine. 2021 Apr;66:103317
pubmed: 33813138